About the Authors
- MyPhuong T. Le
-
Affiliation Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America
- Maximilian T. Lobmeyer
-
Affiliation Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America
- Marcus Campbell
-
Affiliation Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America
- Jing Cheng
-
Affiliation Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, Florida, United States of America
- Zhiying Wang
-
Affiliation Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, United States of America
- Stephen T. Turner
-
Affiliation Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States of America
- Arlene B. Chapman
-
Affiliation Renal Division, Department of Medicine, Emory University, Atlanta, Georgia, United States of America
- Eric Boerwinkle
-
Affiliation Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, United States of America
- John G. Gums
-
Affiliation Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America
- Yan Gong
-
Affiliation Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America
- Richard J. Johnson
-
Affiliation Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Denver, Aurora, Colorado, United States of America
- Julie A. Johnson
-
* E-mail: johnson@cop.ufl.edu
Affiliation Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America
Competing Interests
RJJ has a patent application on inhibition of fructokinase as a mechanism to treat sugar craving and metabolic syndrome. The following lists the patent applications of RJJ: 1) U.S. Provisional application. TARGETING KHK FOR AMELIORATING OBESITY AND SUGAR CRAVING AND IMPROVING KIDNEY FUNCTION. Inventors Richard Johnson, Miguel Lanaspa, and Takuji Ishimoto. Serial No. US2011/046938. 2) U.S. Provisional Application. METHODS FOR FRUCTANASE AND FRUCTOKINASE INHIBITION. Inventors: Richard Johnson, Stephen Dreskin & Miguel Lanaspa-Garcia. Serial No. 61/563,806; Docket No. 11906-003; Ref: CU2981H-PPA1. RJJ also has two lay books, The Sugar Fix: The High-Fructose fallout That Is Making You Fat and Sick (Rodale and Simon and Schuster, 2008), and The Fat Switch (Mercola.com, 2012). None of the other authors declared a conflict of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Primary responsibility for final content: JAJ. Conceived and conducted the PEAR trial: JAJ STT ABC EB JGG. Conceived and conducted GERA1 and GERA2 trials: STT ABC EB. Conceived and designed specific experiments in this paper: M. Le RJJ JAJ. Performed the experiments: M. Le M. Lobmeyer MC. Analyzed the data: M. Le JC ZW YG. Contributed reagents/materials/analysis tools: JAJ STT ABC EB JGG YG JC ZW. Wrote the paper: M. Le.